Evolution Petroleum Schedules Fiscal Third Quarter 2025 Earnings Release and Conference Call
HOUSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Evolution Petroleum Corporation (NYSE American: EPM) ("Evolution" or the "Company") today announced that it plans to release its fiscal third quarter 2025 financial and operating results on Tuesday, May 13, 2025, after the market closes. Additionally, Kelly Loyd, President and Chief Executive Officer, Ryan Stash, Senior Vice President, Chief Financial Officer, and Treasurer, and Mark Bunch, Senior Vice President and Chief Operating Officer, will review the results on a conference call at 10:00 a.m. Central Time on Wednesday, May 14, 2025.
Conference Call and Webcast Details
Date: Wednesday, May 14, 2025Time: 10:00 a.m. Central TimeDial-In: (844) 481-2813International Dial-In: (412) 317-0677Note: Dial-in participants should ask to join the Evolution Petroleum Corporation call.Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ASNQRrWs
A webcast replay will be available through May 14, 2026, via the webcast link above and on Evolution's website at www.ir.evolutionpetroleum.com.
About Evolution Petroleum
Evolution Petroleum Corporation is an independent energy company focused on maximizing total shareholder returns through the ownership of and investment in onshore oil and natural gas properties in the U.S. The Company aims to build and maintain a diversified portfolio of long-life oil and natural gas properties through acquisitions, selective development opportunities, production enhancements, and other exploitation efforts. Visit www.evolutionpetroleum.com for more information.
ContactInvestor Relations(713) 935-0122ir@evolutionpetroleum.com
This press release was published by a CLEAR® Verified individual.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lucasys Income Tax Suite Launches on SAP® Store
Lucasys suite of tax applications now available on the SAP store ATLANTA, June 10, 2025 (GLOBE NEWSWIRE) -- Lucasys, a leading cloud software and service provider for rate-regulated utilities, today announced that its suite of tax applications – including Lucasys Tax Depreciation, Deferred Tax, TBBS, and Copilot – is now available on the SAP® Store, the digital marketplace for SAP and partner offerings. This milestone follows Lucasys' recent partnership within the SAP® PartnerEdge® Open Ecosystem. By integrating with SAP S/4HANA® and other SAP solutions, these applications provide a seamless experience for customers managing complex tax and regulatory requirements. 'Bringing Lucasys Tax applications to the SAP Store underscores our commitment to fostering innovation and flexibility for utilities and asset-intensive businesses,' said Daniel Chang, Chief Operating Officer at Lucasys. 'With this integration, customers can enhance their SAP environments with modern, purpose-built tax solutions that simplify processes, improve compliance, and unlock actionable insights.' Lucasys' tax applications are designed to streamline and automate critical tax processes, including tax depreciation and deferred tax management, while delivering unparalleled usability and security. The modular architecture and deep regulatory support of these solutions ensure that customers can adapt to changing industry demands and achieve long-term operational excellence. Key Features of the Lucasys Income Tax Suite: Integrated Tax Applications: Single integrated experience across tax applications used for tax accounting, tax compliance, and tax forecasting. Enhanced Usability: Simplified workflows reduce the data maintenance burden for end users and facilitate onboarding and training. Flexible Reporting: Robust, user-driven reporting allows for greater visibility and data confidence. Data-Driven Insights: Provides actionable analytics to facilitate strategic tax planning. Scalable Solutions: Tailored for large enterprises and asset-intensive organizations. To learn more about Lucasys' solutions and their availability in the SAP Store, visit and SAP® Store. About Lucasys Lucasys provides software and technology-enabled services to empower finance, accounting, and tax professionals in asset-intensive industries to optimize the financial performance of their fixed assets and proactively meet changing regulatory and compliance requirements. With a core focus on rate-regulated utilities, Lucasys provides the industry and domain expertise utilities require to meet their business objectives. To learn more about Lucasys, visit A photo accompanying this announcement is available at CONTACT: Contact: Tommy Ferguson, CMO, Lucasys 1-844-582-2797 contact@
Yahoo
an hour ago
- Yahoo
ARGAN signed a new lease for 7,000 sq.m as part of its Aut0nom® in Serris (77)
ARGAN signed a new lease for 7,000 sq.m as part of its Aut0nom® in Serris (77) ARGAN announced that its Aut0nom® logistics site in Serris (77), in the immediate suburbs surrounding Paris in the Eastern part of the Île-de-France region, is re-rented to ZyCOM, a new client specializing in the distribution of networks and telecom material. Source : ARGAN This logistics site is ideally located on the A4 French highway. This state of the art logistics platform will welcome this July a new operator on a warehousing surface of around 7,000 sq.m, completed by 400 sq.m of offices. This new location will be used as a national logistics hub for the different entities of the ZyCOM group, which has set the target to optimize its distribution operations over the whole national territory. The very first Aut0nom® Delivered in 2022, this building was the first Aut0nom® developed by ARGAN. Gas is thus banned and replaced by electric heat pumps, the building generates and uses its own green energy thanks to a photovoltaic power station combined with batteries for energy storage. Additionally, a building Management System helps the operator manage and monitor energy consumption. All this equipment led to a BREEAM Very Good certification of our Serris Aut0nom® . Since 2022, Aut0nom® projects have been deployed all over the French territory with now 15 buildings under this label. ARGAN has a portfolio representing close to 4 million sq.m rented at 100% Ronan Le Lan, Chairman of ARGAN's Executive Board: 'The signing of this new lease means our portfolio of 100 warehouses representing 3.7 sq.m is maintaining an occupancy of 100%. This performance testifies to ARGAN's teams expertise in terms of rental management. Additionally, the Serris (77) site holds a particular place in our history. It was indeed the first prototype of the Aut0nom® standard and its fast re-renting confirmed the relevance of this virtuous logistics real estate piece, which is environmentally friendly'. Christophe Valentin, Senior Project Manager of ZyCOM: 'The technical and environmental qualities of this Aut0nom®-labelled site meet our high environmental ambitions. We are pleased to integrate this new workspace, which will support our continued growth.' This operation was concluded with the help of CBRE teams, which advised both parties in this transaction. 2025 financial calendar (Publication of the press release after closing of the stock exchange) July 1: Net sales of 2nd quarter 2025 July 17: Half-year results 2025 October 1: Net sales of 3rd quarter 2025 2026 financial calendar (Publication of the press release after closing of the stock exchange) January 5: Net sales of 4th quarter 2025 January 22: Annual results 2025 March 26: General Assembly 2026 About ARGAN ARGAN is the only French real estate company specializing in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT and is the leading player of its market in France. Building on a unique customer-centric approach, ARGAN develops PREMIUM and Au0nom® -labelled – i.e., carbon-neutral in use – pre-let warehouses for blue-chip companies, with tailor-made services throughout all project phases from the development milestones to the rental management. As at December 31, 2024, ARGAN represented a portfolio of 3.7 million sq.m, with about a hundred warehouses solely located in the continental area of France. Appraised at a total of €3.9 billion, this portfolio generates a yearly rental income of close to €205 million (yearly rental income based on the portfolio delivered as at Dec. 31, 2024). Profitability, well-mastered debt and sustainability are at the heart of ARGAN's DNA. The financial solidity of the Group's model is notably reflected in its Investment-grade rating (BBB- with a stable outlook) with Standard & Poor's. ARGAN is also deploying a committed ESG policy addressing all its stakeholders. Achievements as part of this roadmap are regularly recognized by third-party agencies such as Sustainalytics (low extra-financial risk), Ethifinance (gold medal) and Ecovadis (sliver medal – top 15% amongst rated companies).ARGAN is a listed real estate investment company (French SIIC), on Compartment A of Euronext Paris (ISIN FR0010481960 - ARG) and is included in the Euronext SBF 120, CAC All-Share, EPRA Europe and IEIF SIIC France Francis Albertinelli – CFO Aymar de Germay – General SecretarySamy Bensaid – Head of Investor RelationsPhone: +33 1 47 47 47 40 E-mail: contact@ Marlène Brisset – Media relationsPhone: +33 6 59 42 29 35E-mail: argan@ Attachment 20250610 - Signing of ZycomError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress
UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders. The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance. Biovica's financial targets: FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million FY 2025/26: Net sales of SEK 50 million FY 2026/27: Net sales of SEK 150 million With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27. The expected distribution of revenues during FY25/26 and FY 26/27 are: 65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships 30% from pharma services, based on ongoing and future biomarker collaborations 5% from European partners, through distributor and lab agreements across 18 territories "These targets reflect the solid groundwork we have laid over the past years," says Anders Rylander, CEO of Biovica. "We've achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up. The pieces are in place to deliver on our vision-improving outcomes for patients, optimizing care for providers, and generating long-term value for shareholders." Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-10 18:31 CEST. Attachments Biovica announces financial targets following key partnerships and commercial progress SOURCE: Biovica International View the original press release on ACCESS Newswire
